BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19

NEXT STORY
Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection
PREV STORY
LexaGene Provides Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights

author_avatar
NASDAQ Market News

The North America RNAi therapeutics market is expected to reach US$ 598.60 million by 2027 from US$ 302.77 million in 2019

author_avatar
NASDAQ Market News

ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®

author_avatar
NASDAQ Market News